– UK, London – Ergomed plc (LSE:ERGO), a company focused on providing specialised services to the pharmaceutical industry, today announced that Michael Spiteri has joined the Board as Non-Executive Director with immediate effect.
The company also announced that Andrew Mackie is stepping down as Chief Business Officer and Board member following the Company’s announcement in April to shift its strategy to focus on services.
Peter George, Chairman of Ergomed, said: “The use of digital technology to drive both efficiency and accuracy is a strategic priority for Ergomed, particularly in our pharmacovigilance business. As a leader in the world of digitization, automation and AI, Michael’s experience and counsel will be invaluable to our Board as we optimise the Group’s operations and drive growth. I look forward to his input and welcome him to the team.
“I would also like to recognize Andrew’s contribution to Ergomed over the last three years as an executive and for several years before that as a consultant. We wish him well in his future endeavours.”
About Michael Spiteri
Michael has nearly 30 years’ experience working in information technology and digital transformation. At Santander’s UK Corporate and Commercial Banking business, he is responsible for digital strategy, process transformation and digital implementation across all areas of the business including automation and machine learning. Prior to Santander, Michael held partner roles at Elixirr Partners LLP and PricewaterhouseCoopers LLP and senior executive roles at Accenture and IBM as well as senior management roles at HCL Axon and Oracle with a focus on financial services clients. Michael received a BSc in Mechanical Engineering from Paisley College of Technology.
Michael Spiteri, Non-Executive Director of Ergomed, said: “Ergomed is at a key juncture as it embraces and takes advantage of the opportunities presented by automation and AI. I’m delighted to be joining the Ergomed Board and I am looking forward to contributing to the roll-out of its digitization strategy”.
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services. Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes.
For more information : http://www.ergomedplc.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
